| 研究課題/領域番号 |
22K07286
|
|---|
| 研究機関 | 国際医療福祉大学 |
|---|
研究代表者 |
|
|---|
| 研究分担者 |
三沢 彩 国際医療福祉大学, 医学部, 講師 (20598453)
大多 茂樹 国際医療福祉大学, 医学部, 准教授 (20365406)
河上 裕 国際医療福祉大学, 医学部, 教授 (50161287)
|
|---|
| 研究期間 (年度) |
2022-04-01 – 2025-03-31
|
| キーワード | lipid lowering agents / statins / T cell immune function / inhibitory molecules / anti-tumor responses |
|---|
| 研究実績の概要 |
Nowadays, immune checkpoint inhibitor combination therapies have been greatly focused on cancer immunotherapy. Anti-tumor T cells are key effectors and immuno-metabolic modulations in the tumor microenvironment (TME) are good regulators to improve the efficacy of anti-PD1/L1 treatment. The main purpose of this study are (1) to evaluate the immunological roles of statins (HMG-CoA reductase inhibitors) in order to promote the anti-tumor responses, and (2) to study the possible mechanisms of anti-tumor effects of statins. At first, I examined the role of statins on immunological responses of human immune cells, particularly T lymphocytes from human PBMC. I observed that statins prevented the dysfunction of human T cells by suppressing the T cell inhibitory checkpoint molecules.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
The immunological analyses using human PBMC might depend on the availability of blood from healthy donors. However, the current data showed positive findings so that it will be able to perform steadily according to research plans.
|
| 今後の研究の推進方策 |
The order of research plans became slightly different due to the results of certain experiments. I examined in vitro study first to observe the effects of statins on human immune cells as our final goal is to obtain the supportive scientific data that can be applicable on human (cancer patients).
As next step, I plan to perform in vivo analysis using tumor bearing mouse models to study the cellular and molecular immunological responses of statins in the tumor microenvironment.
|
| 次年度使用額が生じた理由 |
In academic year 2023, I would like to investigate the anti-tumor effect of statins using tumor bearing mouse models treated with anti-PD-1 antibody and statins combination therapy. I will also continue in vitro analysis of immunological responses of statins on human immune cells to estimate the possible cellular mechanisms of statins in cancer patients.
Therefore, I will spend research fund to purchase laboratory mice, culture medium, reagents and some antibodies for immunological analysis. I also need to purchase the commercially available statin compound for the in vivo experiments.
|
